RoslinCT and Lykan Bioscience, companies involved in contract development and manufacturing for cell therapies, have been granted a Manufacturer’s Authorization License (MIA) for commercial manufacturing of cell therapy products from the Medicines and Healthcare products Regulatory Agency (MHRA), following a successful inspection at their Edinburgh, UK facility.
Completed in late 2021, RoslinCT’s newest 1,600 square-meter state-of-the-art facility, located in Edinburgh’s BioQuarter, was designed to operate as a flexible and scalable manufacturing hub, housing five cGMP clean rooms and a dedicated training laboratory. The cGMP facility has been designed and purpose-built specifically to accommodate cell therapy manufacturing processes for both allogeneic and autologous therapies with or without genome editing requirements.
